Cargando…

Helper T Lymphocyte Response in the Peripheral Blood of Patients with Intraepithelial Neoplasia Submitted to Immunotherapy with Pegylated Interferon-α

Immunotherapy in cancer patients is a very promising treatment and the development of new protocols and the study of the mechanisms of regression is imperative. The objective of this study was to evaluate the production of cytokines in helper T (CD4(+)) lymphocytes during immunotherapy with pegylate...

Descripción completa

Detalles Bibliográficos
Autores principales: Michelin, Márcia Antoniazi, Montes, Letícia, Nomelini, Rosekeila Simões, Trovó, Marco Aurélio, Murta, Eddie Fernando Candido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4394488/
https://www.ncbi.nlm.nih.gov/pubmed/25764160
http://dx.doi.org/10.3390/ijms16035497
_version_ 1782366295870668800
author Michelin, Márcia Antoniazi
Montes, Letícia
Nomelini, Rosekeila Simões
Trovó, Marco Aurélio
Murta, Eddie Fernando Candido
author_facet Michelin, Márcia Antoniazi
Montes, Letícia
Nomelini, Rosekeila Simões
Trovó, Marco Aurélio
Murta, Eddie Fernando Candido
author_sort Michelin, Márcia Antoniazi
collection PubMed
description Immunotherapy in cancer patients is a very promising treatment and the development of new protocols and the study of the mechanisms of regression is imperative. The objective of this study was to evaluate the production of cytokines in helper T (CD4(+)) lymphocytes during immunotherapy with pegylated IFN-α in patients with cervical intraepithelial neoplasia (CIN). We conducted a prospective study with 17 patients with CIN II-III using immunotherapy with pegylated IFN-α subcutaneouly weekly, and using flow cytometry we evaluated the peripheric CD4(+) T lymphocytes. The results show that in the regression group the patients presented a significant increase in the amount of IFN-γ during the entire immunotherapy, compared with the group without a response. The amount of CD4(+) T lymphocytes positive for IL-2, IL-4, IL-10 and TGF-β is significantly lower in patients with good clinical response. The results also demonstrate that patients with regression have a higher amount of intracellular TNF-α in CD4(+) T lymphocytes before the start of treatment. Analyzing these data sets, it can be concluded that immunotherapy is a viable clinical treatment for patients with high-grade CIN and that the regression is dependent on the change in the immune response to a Th1 pattern.
format Online
Article
Text
id pubmed-4394488
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-43944882015-05-21 Helper T Lymphocyte Response in the Peripheral Blood of Patients with Intraepithelial Neoplasia Submitted to Immunotherapy with Pegylated Interferon-α Michelin, Márcia Antoniazi Montes, Letícia Nomelini, Rosekeila Simões Trovó, Marco Aurélio Murta, Eddie Fernando Candido Int J Mol Sci Article Immunotherapy in cancer patients is a very promising treatment and the development of new protocols and the study of the mechanisms of regression is imperative. The objective of this study was to evaluate the production of cytokines in helper T (CD4(+)) lymphocytes during immunotherapy with pegylated IFN-α in patients with cervical intraepithelial neoplasia (CIN). We conducted a prospective study with 17 patients with CIN II-III using immunotherapy with pegylated IFN-α subcutaneouly weekly, and using flow cytometry we evaluated the peripheric CD4(+) T lymphocytes. The results show that in the regression group the patients presented a significant increase in the amount of IFN-γ during the entire immunotherapy, compared with the group without a response. The amount of CD4(+) T lymphocytes positive for IL-2, IL-4, IL-10 and TGF-β is significantly lower in patients with good clinical response. The results also demonstrate that patients with regression have a higher amount of intracellular TNF-α in CD4(+) T lymphocytes before the start of treatment. Analyzing these data sets, it can be concluded that immunotherapy is a viable clinical treatment for patients with high-grade CIN and that the regression is dependent on the change in the immune response to a Th1 pattern. MDPI 2015-03-10 /pmc/articles/PMC4394488/ /pubmed/25764160 http://dx.doi.org/10.3390/ijms16035497 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Michelin, Márcia Antoniazi
Montes, Letícia
Nomelini, Rosekeila Simões
Trovó, Marco Aurélio
Murta, Eddie Fernando Candido
Helper T Lymphocyte Response in the Peripheral Blood of Patients with Intraepithelial Neoplasia Submitted to Immunotherapy with Pegylated Interferon-α
title Helper T Lymphocyte Response in the Peripheral Blood of Patients with Intraepithelial Neoplasia Submitted to Immunotherapy with Pegylated Interferon-α
title_full Helper T Lymphocyte Response in the Peripheral Blood of Patients with Intraepithelial Neoplasia Submitted to Immunotherapy with Pegylated Interferon-α
title_fullStr Helper T Lymphocyte Response in the Peripheral Blood of Patients with Intraepithelial Neoplasia Submitted to Immunotherapy with Pegylated Interferon-α
title_full_unstemmed Helper T Lymphocyte Response in the Peripheral Blood of Patients with Intraepithelial Neoplasia Submitted to Immunotherapy with Pegylated Interferon-α
title_short Helper T Lymphocyte Response in the Peripheral Blood of Patients with Intraepithelial Neoplasia Submitted to Immunotherapy with Pegylated Interferon-α
title_sort helper t lymphocyte response in the peripheral blood of patients with intraepithelial neoplasia submitted to immunotherapy with pegylated interferon-α
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4394488/
https://www.ncbi.nlm.nih.gov/pubmed/25764160
http://dx.doi.org/10.3390/ijms16035497
work_keys_str_mv AT michelinmarciaantoniazi helpertlymphocyteresponseintheperipheralbloodofpatientswithintraepithelialneoplasiasubmittedtoimmunotherapywithpegylatedinterferona
AT montesleticia helpertlymphocyteresponseintheperipheralbloodofpatientswithintraepithelialneoplasiasubmittedtoimmunotherapywithpegylatedinterferona
AT nomelinirosekeilasimoes helpertlymphocyteresponseintheperipheralbloodofpatientswithintraepithelialneoplasiasubmittedtoimmunotherapywithpegylatedinterferona
AT trovomarcoaurelio helpertlymphocyteresponseintheperipheralbloodofpatientswithintraepithelialneoplasiasubmittedtoimmunotherapywithpegylatedinterferona
AT murtaeddiefernandocandido helpertlymphocyteresponseintheperipheralbloodofpatientswithintraepithelialneoplasiasubmittedtoimmunotherapywithpegylatedinterferona